Cholesterol and triglyceride fats are transported as part of lipoprotein particles in the bloodstream. The various lipoprotein classes Low Density Lipoprotein (LDL) that carry most part of the blood cholesterol, Very Low Density Lipoprotein (VLDL), which carry most of the blood triglycerides, High Density Lipoprotein (HDL) and Chylomicrons. LDL also found as serum cholesterol plays a significant role in coronary heart diseases. The role of these lipoproteins is quite independent of other risk factors and is quite predictive that could be easily assessed. The present article is focused on the estimation of plasma lipoprotein (a) [Lp(a)] level in AMI patients along with their cardiac Troponin-I levels to study the correlation between the two and to look into the possibility of dual marker approach to deal with complications associated with acute myocardial infarction. Lp(a) is a major risk factor of several cardiovascular diseases, namely atherosclerotic vascular diseases, aortic calcification, and perhaps also venous thromboembolic diseases and hence could be a prominent therapeutic target for primary and secondary prevention. This calls for the development of a safe and effective means of lowering Lp(a) that will provide an opportunity to conduct intervention trials to further decipher its contribution in the etiology of CHD